We use analytics and advertising cookies, which you can accept or reject; see our privacy policy.

Current choice:

Fig. 1 · Structure
Cat. No.
A12029
CAS No.
154-23-4
Formula
C15H14O6
Mol. Weight
290.27

Documents & Downloads

Catechin

Cat. No. A12029 CAS 154-23-4
Catechin is a natural flavonoid that has chemopreventive and antitumor properties.

In Stock

Publications for Catechin

4 publications citing this product

  1. Rashmi Rawat, .et al. , Food Chemistry Advances, 2022, 1: 100092
  2. Vergne MJ, .et al. , J Food Sci, 2018, May;83(5):1258-1264 PMID: 29668030
  3. Md Shajedul Islam, .et al. , Innovative food science & emerging technologies, 2016, v.34 pp. 344-351
  4. Islam MS, .et al. , J Agric Food Chem, 2016, Oct 10 PMID: 27632812
Notify me when the price drops

For laboratory research use only. We do not sell to patients.

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

In oxidatively challenged N9 microglia, (+)-catechin was associated with less sustained nuclear NF-κB p65 accumulation and IκBα phosphorylation. Total p65 was reported unchanged. This cellular time course does not establish direct inhibition of IκB kinase. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
COX-1 80 μM
COX-2 130 μM

In Vitro Studies

Following tBHP exposure, (+)-catechin increased the MTT viability readout in murine N9 microglia. The reported peak was 64.63% at 1 mM after 24 h; the response declined at 2 mM. These results concern an isolated cell-line oxidative-injury model. [1]

MTT response after oxidative challenge in N9 microglia

Cell-based study · Murine N9 microglial cell line exposed to tert-butylhydroperoxide (tBHP) [1]

MTT viability increased after catechin treatment following tBHP exposure. The response peaked at 1 mM and was lower at 2 mM; this is not a monotonic concentration response or a potency estimate.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
MTT viability relative to the assay referenceViability (%) 64.63% at 1 mM; n = 3; plotted error bars are mean ± S.D. (replicate type unspecified).[1]
Shape of catechin concentration responseQualitative concentration response 2 mM produced lower viability than 1 mM; no exact 2 mM value extracted.[1]

Literature-Reported Treatment Conditions

Treatment concentration
(+)-Catechin: 0.06, 0.13, 0.25, 0.5, 1 and 2 mM (Fig. 2). Oxidative challenge: 0.3 mM tBHP.
Exposure duration
tBHP exposure for 1 h before catechin; MTT endpoint at 24 h.
Method
Catechin added after tBHP pretreatment; tBHP-only comparator. Cell culture used IMDM with 5% FBS and 5% horse serum.
Co-treatment
Catechin treatment following an oxidative challenge; no second therapeutic agent in the selected dose-response experiment.
Reported limits
Catechin solvent/vehicle and the biological versus technical meaning of n = 3 are not specified. A catechin-only viability arm is not shown in Fig. 2. The normalization calculation for MTT percent viability is not detailed.
Methods and source locations

Compound reported in the paper: (+)-Catechin; Compound label in the paper: (+)-catechin

Results concern the paper's isolated (+)-catechin, not an Adooq lot; no validation of the supplied product is implied.

Methods, pp. 17–18; Fig. 2 p. 18; Results p. 19; Fig. 3 p. 19 (qualitative corroboration only)

MTT viability relative to the assay reference: MTT assay; exact peak stated in Results, not estimated from bars. — Fig. 2, p. 18; Results continuation p. 19

Shape of catechin concentration response: Visual inspection of Fig. 2. — Fig. 2, p. 18

NF-κB localization during catechin treatment after oxidative challenge

Cell-based study · tBHP-exposed murine N9 microglia; nuclear, cytoplasmic and total-cell protein fractions [1]

Catechin treatment was associated with less sustained nuclear NF-κB p65 and IκBα phosphorylation than tBHP alone. Total p65 showed no reported significant change. These blots support pathway-associated cellular effects rather than direct target inhibition.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Nuclear NF-κB p65 and phosphorylated IκBαQualitative immunoblot time course With catechin, nuclear p65 rose from 2 to 4 h then declined; without catechin it remained elevated from 4 to 10 h. Phosphorylated IκBα declined from 4 to 10 h with catechin.[1]
Total NF-κB p65 expressionReported unchanged endpoint No significant change reported in total NF-κB p65. No numerical effect size or statistical estimate supplied for the displayed blot.[1]

Literature-Reported Treatment Conditions

Treatment concentration
0.5 mM (+)-catechin after 0.3 mM tBHP.
Exposure duration
tBHP pretreatment for 1 h; catechin time course 1, 2, 4, 6 and 10 h (Fig. 7).
Method
Subcellular fractionation and Western blotting with tBHP-only time-course controls.
Co-treatment
Oxidative challenge followed by catechin; no second therapeutic treatment.
Reported limits
Catechin solvent/vehicle, blot replicate count and quantitative densitometry are not specified for Fig. 7. No direct IκB kinase activity/binding experiment or pathway perturbation establishes the proposed causal chain.
Methods and source locations

Compound reported in the paper: (+)-Catechin; Compound label in the paper: (+)-catechin

Results concern the paper's isolated (+)-catechin, not an Adooq lot; no validation of the supplied product is implied.

Methods: Chemicals, nuclear/cytoplasmic extracts and Western blots, pp. 17–18; Results p. 20; Fig. 7 p. 22

Nuclear NF-κB p65 and phosphorylated IκBα: Western blots of subcellular fractions; β-actin and C/EBP bands are displayed as controls. — Fig. 7, p. 22; Results, p. 20

Total NF-κB p65 expression: Total-cell p65 immunoblot compared alongside nuclear/cytoplasmic p65. — Fig. 7, p. 22; Results, p. 20

Specifications

Manufacturer Adooq Bioscience
CAS Number 154-23-4
Formula C15H14O6
Molecular Weight 290.27
SMILES
C1[C@@H]([C@H](OC2=CC(=CC(=C21)O)O)C3=CC(=C(C=C3)O)O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 57 mg/mL (196.37 mM)
Water 57 mg/mL (196.37 mM)
Ethanol 57 mg/mL (196.37 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

From the Knowledge Base

Browse all articles

Research References

  1. [1] Qing Huang, Li-Jun Wu, Shin-ichi Tashiro, et al. (+)-Catechin, an Ingredient of Green Tea, Protects Murine Microglia From Oxidative Stress-Induced DNA Damage and Cell Cycle Arrest Journal of Pharmacological Sciences (2005). PMID: 15879681 DOI: 10.1254/jphs.FPJ04053X Source material

Publications

4 publications citing this product

  1. Rashmi Rawat, .et al. , Food Chemistry Advances, 2022, 1: 100092
  2. Vergne MJ, .et al. , J Food Sci, 2018, May;83(5):1258-1264 PMID: 29668030
  3. Md Shajedul Islam, .et al. , Innovative food science & emerging technologies, 2016, v.34 pp. 344-351
  4. Islam MS, .et al. , J Agric Food Chem, 2016, Oct 10 PMID: 27632812

Added to your cart

View Cart Checkout
Loading...